- Cadralazine
-
- $39.00
-
2026-05-11
- CAS:64241-34-5
- Purity: 99.65%
- Supply Ability: 10g
- Cadralazine
-
-
2020-05-10
- CAS:64241-34-5
- Min. Order: 1KG
- Purity: 99.0%
- Supply Ability: 500 MT
|
| | Cadralazine Basic information |
| Product Name: | Cadralazine | | Synonyms: | HYDRAZINECARBOXYLIC ACID, 2-[6-[ETHYL(2-HYDROXYPROPYL)AMINO]-3-PYRIDAZINYL]-, ETHYL ESTER;Cadralazine;Cadral;Cadraten;Cadrilan;CGP 18684E;DC 826;ISF 2469 | | CAS: | 64241-34-5 | | MF: | C12H21N5O3 | | MW: | 283.33 | | EINECS: | | | Product Categories: | | | Mol File: | 64241-34-5.mol |  |
| | Cadralazine Chemical Properties |
| Melting point | 160-162° | | Boiling point | 425.88°C (rough estimate) | | density | 1.1585 (rough estimate) | | refractive index | 1.6500 (estimate) | | storage temp. | 2-8°C | | solubility | DMSO : 250 mg/mL (882.36 mM; ultrasonic and warming and heat to 60°C) | | pka | 6.0(at 25℃) | | form | Solid | | color | White to off-white | | CAS DataBase Reference | 64241-34-5 |
| Toxicity | LD50 in rats, dogs (mg/kg): 269, approx 400 i.v.; 2060, >2000 orally (Semeraro); in mice (mg/kg): 700 i.p. (Parravicini) |
| | Cadralazine Usage And Synthesis |
| Description | Cadralazine is a vasodilatory antihypertensive reportedly better-tolerated and
longer-acting than hydralazine. It is useful as a second-line treatment in the management
of hypertension. | | Chemical Properties | Crystallized in acetone, melting point 160-162°C. pKa 6.0. UV max absorption: 248, 340m (ε22100, 2250). Solubility (mg/m1): water 1.3, hydrochloric acid 235.0, dimethyl sulfoxide 323.0, methanol 21.0, dioxane 18.6, chloroform 8.5, ether, benzene, and cyclohexane <0.1. Acute Toxicity LD50 rat, dog (mg/kg): 269, about 400 IV; 2060, >2000 oral. Acute toxicity LD50 rat (mg/kg): 700 intraperitoneal. | | Originator | ISF;（Smith Mine) (Italy) | | Definition | ChEBI: Cadralazine is an organic molecular entity. | | Brand name | Cadraten 21 cpr 20 mg;Cadraten 30 cpr 10 mg;Cadraten 30 cpr 15 mg;Cadratin;Cadrilan. | | World Health Organization (WHO) | Cadralazine, a peripheral vasodilator, was introduced in 1989 for
the treatment of arterial hypertension.In 1992, its association with serious side
effects led to the refusal of registration in Norway. Animal experiments have
demonstrated drug-related impairment of thyroid function as well as potential carcinogenicity and genotoxicity. It remains available for treatment of hypertension
in Italy. |
| | Cadralazine Preparation Products And Raw materials |
|